scholarly journals Six‐month longitudinal antibody kinetics of mRNA COVID‐19 vaccines

2021 ◽  
Author(s):  
Lakshmanan Suresh
Keyword(s):  
Antibody Kinetics ◽  
Kinetics Of

scholarly journals Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases

2021 ◽  
Author(s):  
Xiang-Yang Yao ◽  
Wei Liu ◽  
Zhi-Yong Li ◽  
Hua-Long Xiong ◽  
Ying-Ying Su ◽  
...  
Keyword(s):  
Regression Coefficient ◽  
Control Strategies ◽  
Illness Onset ◽  
Relative Contribution ◽  
Long Time ◽  
Iga Antibody ◽  
Binding Antibody ◽  
Blood Specimens ◽  
Antibody Kinetics ◽  
Kinetics Of

Abstract Background: Knowledge of host immune response after natural SARS-CoV-2 infection is essential for the direction of vaccination and epidemiological control strategies against COVID-19.Methods: Thirty-four COVID-19 patients were enrolled with 244 serial blood specimens (38.1% after hospital discharge) collected to explore the chronological evolution of neutralizing (NAb), total (TAb), IgM, IgG and IgA antibody in parallel.Results: IgG titers reached a peak later (35 days postonset) than those of Nab, Ab, IgM and IgA (25 days postonset). IgM levels declined with an estimated half-life of 35 days postonset, which was more rapid than those of IgA and IgG (73-76 days postonset). All patients remained positive for NAb, IgG and IgA up to 3 months after illness onset. The relative contribution of IgM to NAb was higher than that of IgG (standardized β regression coefficient: 0.53 vs 0.48). However, the relative contribution of IgG to NAb increased and that of IgM further decreased after 6 weeks postonset.Conclusions: This study suggests that SARS-CoV-2 infection induces robust neutralizing and binding antibody responses in patients. Humoral immunity against SARS-CoV-2 acquired by infection may persist for a relatively long time.

scholarly journals Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Antonio Arrieta ◽  
Alvaro E. Galvis ◽  
Tricia Morphew ◽  
Louis Ehwerhemuepha ◽  
Stephanie Osborne ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Antibody Kinetics ◽  
Kinetics Of

scholarly journals Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0241164 ◽  
Author(s):  
Victoria Indenbaum ◽  
Ravit Koren ◽  
Shiri Katz-Likvornik ◽  
Mayan Yitzchaki ◽  
Osnat Halpern ◽  
...  
Keyword(s):  
Igg Antibodies ◽  
Serum Samples ◽  
Igg Antibody ◽  
Past Exposure ◽  
Iga Antibodies ◽  
Global Spread ◽  
Diagnostic Capacity ◽  
Antibody Levels ◽  
Antibody Kinetics ◽  
Kinetics Of

The COVID-19 pandemic and the fast global spread of the disease resulted in unprecedented decline in world trade and travel. A critical priority is, therefore, to quickly develop serological diagnostic capacity and identify individuals with past exposure to SARS-CoV-2. In this study serum samples obtained from 309 persons infected by SARS-CoV-2 and 324 of healthy, uninfected individuals as well as serum from 7 COVID-19 patients with 4–7 samples each ranging between 1–92 days post first positive PCR were tested by an “in house” ELISA which detects IgM, IgA and IgG antibodies against the receptor binding domain (RBD) of SARS-CoV-2. Sensitivity of 47%, 80% and 88% and specificity of 100%, 98% and 98% in detection of IgM, IgA and IgG antibodies, respectively, were observed. IgG antibody levels against the RBD were demonstrated to be up regulated between 1–7 days after COVID-19 detection, earlier than both IgM and IgA antibodies. Study of the antibody kinetics of seven COVID 19 patients revealed that while IgG levels are high and maintained for at least 3 months, IgM and IgA levels decline after a 35–50 days following infection. Altogether, these results highlight the usefulness of the RBD based ELISA, which is both easy and cheap to prepare, to identify COVID-19 patients even at the acute phase. Most importantly our results demonstrate that measuring IgG levels alone is both sufficient and necessary to diagnose past exposure to SARS-CoV-2.

scholarly journals Differential Shedding and Antibody Kinetics of Zika and Chikungunya Viruses, Brazil

2019 ◽  
Vol 25 (2) ◽  
pp. 311-315 ◽  
Author(s):  
Fernando A. Bozza ◽  
Andres Moreira-Soto ◽  
Alexandra Rockstroh ◽  
Carlo Fischer ◽  
Alessandra D. Nascimento ◽  
...  
Keyword(s):  
Antibody Kinetics ◽  
Kinetics Of

scholarly journals The longitudinal kinetics of antibodies in COVID-19 recovered patients over 14 months

2021 ◽  
Author(s):  
Tsuf Eyran ◽  
Anna Vaisman-Mentesh ◽  
Yeal Dror ◽  
Ligal Aizik ◽  
Aya Kigel ◽  
...  
Keyword(s):  
Decision Making ◽  
Decay Rate ◽  
Natural Infection ◽  
Serological Response ◽  
Specific Antibodies ◽  
Antibody Levels ◽  
Antibody Kinetics ◽  
Kinetics Of

Here, we describe the longitudinal kinetics of the serological response in COVID-19 recovered patients over the period of 14 months. The antibody kinetics in a cohort of 200 recovered patients with 89 follow up samples at 2-4 visits reveal that RBD-specific antibodies decay over the period of 14 month following the onset of symptoms. The decay rate is associated with the robustness of the response thus, recovered patients that exhibit elevated antibody levels at the first visit, experience faster decay. We further explored the longitudinal kinetics differences between recovered patients and naive BNT162b2 vaccinees. We found a significantly faster decay in naive vaccinees compared to recovered patients suggesting that the serological memory following natural infection is more robust compared to vaccination. Our data highlights the differences between serological memory induced by natural infection vs. vaccination, facilitating the decision making in Israel regarding the 3rd dose vaccination.

scholarly journals Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers

2020 ◽  
Author(s):  
Tongyang Xiao ◽  
Yanrong Wang ◽  
Jing Yuan ◽  
Haocheng Ye ◽  
Lanlan Wei ◽  
...  
Keyword(s):  
Viral Clearance ◽  
C Reactive Protein ◽  
Viral Kinetics ◽  
Asymptomatic Carriers ◽  
Reactive Protein ◽  
Low Levels ◽  
Immuno Assay ◽  
Antibody Kinetics ◽  
Kinetics Of

AbstractBackgroundAsymptomatic carriers contribute to the spread of Coronavirus Disease 2019 (COVID-19), but their clinical characteristics, viral kinetics, and antibody responses remain unclear.MethodsA total of 56 COVID-19 patients without symptoms at admission and 19 age-matched symptomatic patients were enrolled. RNA of SARS-CoV-2 was tested using transcriptase quantitative PCR, and the total antibodies (Ab), IgG, IgA and IgM against the SARS-CoV-2 were tested using Chemiluminescence Microparticle Immuno Assay.ResultsAmong 56 patients without symptoms at admission, 33 cases displayed symptoms and 23 remained asymptomatic throughout the follow-up period. 43.8% of the asymptomatic carriers were children and none of the asymptomatic cases had recognizable changes in C-reactive protein or interleukin-6, except one 64-year-old patient. The initial threshold cycle value of nasopharyngeal SARS-CoV-2 in asymptomatic carriers was similar to that in pre-symptomatic and symptomatic patients, but the communicable period of asymptomatic carriers (9.63 days) was shorter than pre-symptomatic patients (13.6 days). There was no obvious differences of the seropositive conversion rate of total Ab, IgG, and IgA among the three groups, though the rates of IgM varied largely. The average peak IgG and IgM COI of asymptomatic cases was 3.5 and 0.8, respectively, which is also lower than those in symptomatic patients with peaked IgG and IgM COI of 4.5 and 2.4 (p <0.05).ConclusionYoung COVID-19 patients seem to be asymptomatic cases with early clearance of SARS-CoV-2 and low levels of IgM generation but high total Ab, IgG and IgA. Our findings provide empirical information for viral clearance and antibody kinetics of asymptomatic COVID-19 patients.

scholarly journals Antibodies and antigen kinetics in patients with COVID-19

2021 ◽  
Author(s):  
Mi Zhou ◽  
Qingfeng Li ◽  
YongLi Zheng ◽  
Xue Cong ◽  
Guoqing Li ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Serological Test ◽  
Specific Antigen ◽  
Fold Increase ◽  
Serum Samples ◽  
Positive Rate ◽  
Asymptomatic Infections ◽  
Antibody Kinetics ◽  
Antigen Testing ◽  
Kinetics Of

Abstract The antigen and antibody kinetics of SARS-CoV-2 infected patients remains unclear, and the clinical values of the serological test have not been completely elucidated. A total of 154 serum samples from 13 patients with COVID-19 infection were collected at about three-day intervals during hospitalization. Samples were screened for SARS-CoV-2-specific total antibodies (TAb), IgA, IgM, IgG, and antigen (Ag) using chemiluminescent microparticle immunoassays (CMIA). The overall seroconversion and/or four-fold increase rates of TAb, IgA, IgM, and IgG during hospitalization were 92.31%, 92.31%, 84.62%, and 92.31%, respectively. However, within a week of onset, antibodies were present in <50% of the patients. The combination of “Ag and/or TAb” maintained the positive rate at 81.82% during the first three days after symptom onset and quickly enhanced to 92.31% during 4–6 days after the symptom onset. The seropositive median day of Ag was two days after symptom onset. Among patients who underwent IgM and IgG seroconversion, the seroconversion median days of IgA, TAb, IgM, and IgG were 9.5 days, 10 days, 11 days, and 11.5 days after the symptom onset, respectively. Serological testing, especially virus-specific antigen testing, may be helpful for early identification of suspected patients and asymptomatic infections.

scholarly journals Antibody kinetics to SARS-CoV-2 at 13.5 months, by disease severity

2021 ◽  
Author(s):  
Concepcion Violan ◽  
Pere Toran ◽  
Bibiana Quirant ◽  
Noemi Lamonja-Vicente ◽  
Lucia A Carrasco-Ribelles ◽  
...  
Keyword(s):  
Disease Severity ◽  
Mixed Models ◽  
Kinetic Modelling ◽  
Health Policies ◽  
Public Health Policies ◽  
Disease Spectrum ◽  
Moderate Disease ◽  
Humoral Responses ◽  
Antibody Kinetics ◽  
Kinetics Of

Background: Understanding humoral responses and seroprevalence in SARS-CoV-2 infection is essential for guiding vaccination strategies in both infected and uninfected individuals. Methods: We determine the kinetics of IgM against the nucleocapsid (N) and IgG against the spike (S) and N proteins of SARS-CoV-2 in a cohort of 860 health professionals (healthy and infected) in northern Barcelona. We model the kinetics of IgG and IgM at nine time points over 13.5 months from infection, using non-linear mixed models by sex and clinical disease severity. Results: Of the 781 participants who were followed up, 478 (61.2%) became infected with SARS-CoV-2. Significant differences were found for the three antibodies by disease severity and sex. At day 270 after diagnosis, median IgM(N) levels were already below the positivity threshold in patients with asymptomatic and mild-moderate disease, while IgG(N, S) levels remained positive to days 360 and 270, respectively. Kinetic modelling showed a general rise in both IgM(N) and IgG(N) levels up to day 30, followed by a decay whose rate depended on disease severity. IgG(S) levels increased at day 15 and remained relatively constant over time. Conclusions: We describe kinetic models of IgM(N) and IgG(N, S) SARS-CoV-2 antibodies at 13.5 months from infection and disease spectrum. Our analyses delineate differences in the kinetics of IgM and IgG over a year and differences in the levels of IgM and IgG as early as 15 days from symptoms onset in severe cases. These results can inform public health policies around vaccination criteria.

scholarly journals Early and long-term antibody kinetics of asymptomatic and mild disease COVID-19 patients

2021 ◽  
Author(s):  
Shai Efrati ◽  
Merav Catalogna ◽  
Ramzia Abu Hamed ◽  
Amir Hadanny ◽  
Adina Bar-Chaim ◽  
...  
Keyword(s):  
Time Course ◽  
Acute Infection ◽  
Evaluation Procedure ◽  
Serum Samples ◽  
Tree Model ◽  
Mild Disease ◽  
Study Participants ◽  
Antibody Kinetics ◽  
Kinetics Of

Abstract Most patients infected with SARS-CoV-19 are asymptomatic or mildly symptomatic. However, the early and late antibody kinetics in those patients have not yet been fully defined. Confirmed SARS-CoV-2 patients, and their household contacts were evaluated over a period four months. The evaluation procedure included symptom monitoring, viral load and serology analysis every ten days. A total of 1334 serum samples were collected from 135 patients and analyzed using three assays for IgG-N, IgG-S and IgM antibodies. Of the study participants, 97% were seropositive during the study and two distinct clusters were identified. These clusters were significantly different in their inflammatory related symptoms. Peak IgG-S was 45.8 AU/ml for cluster 1 and 71.5 AU/ml for cluster 2 (P = 0.004), whereas IgG-N peaks were 4.5 and 5.8 (P = 0.001) respectively. Finally, a decision tree model was designed to predict the disease phase based on the serological titer levels, and had an overall accuracy of 80.7%. The specific profile of seroconversion and decay of serum antibodies can be used to predict the time course from the acute infection.

Sign in / Sign up

Export Citation Format

Share Document